New kind of flu shot is on the way as the FDA approves Moderna's mRNA-based vaccine

The Food and Drug Administration has approved mFlusiva, a new flu vaccine developed by Moderna for adults aged 50 or older. This is the first flu shot created using the mRNA technology that was essential in addressing the COVID-19 pandemic. While other flu vaccine brands are already reaching pharmacies for the autumn season, Moderna announced that this new version will soon be available at select retailers, marking a significant shift in influenza vaccination methods for older populations.